Want to see IVVD full AI Analyst Report?
IVVD Stock Chart & Stats
$0.61
<$0.01(0.49%)
At close: 4:00 PM EDT
$0.61
<$0.01(0.49%)
Day’s Range― - ―
52-Week Range$0.48 - $3.07
Previous CloseN/A
Volume1.33M
Average Volume (3M)5.17M
Market Cap
$218.01M
Enterprise Value$227.04
Total Cash (Recent Filing)$184.15M
Total Debt (Recent Filing)$8.63M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 19, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding294,607,450
10 Day Avg. Volume2,813,339
30 Day Avg. Volume5,173,640
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.76
Price to Sales (P/S)7.96
P/FCF Ratio-7.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside1539.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$63.30M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsTTM gross margin near 93% signals durable unit economics for monoclonal product sales. High contribution per dose supports scalability of revenue, funds continued R&D and commercialization, and provides a margin cushion versus lower‑margin competitors as volumes expand.
Low Leverage / Balance Sheet FlexibilityMinimal debt relative to equity reduces refinancing and interest‑rate risk, preserving optionality for equity, partnerships or opportunistic financings. This balance‑sheet strength supports continued pivotal trials and commercialization investment without near‑term debt pressure.
Commercial Traction & De‑risked Pivotal ProgressSimultaneous commercial growth (PEMGARDA +22% YoY), resumed/upsized DECLARATION recruitment, IDMC reducing monitoring, and confirmed neutralization vs BA.3.2 materially reduce clinical and go‑to‑market risk. These factors enhance launch readiness and long‑term product relevance.
Bears Say
Sustained Cash Burn / Negative Free Cash FlowSignificant negative operating and free cash flow (~-$79M TTM) reflects ongoing clinical and commercial investment. Persistent cash burn raises financing and dilution risk, constrains strategic flexibility, and could pressure timelines or program scope if access to capital weakens.
Regulatory Transition Risk For PEMGARDAThe announced end of the EUA creates structural regulatory uncertainty: Invivyd must secure a post‑EUA approval (e.g., BLA) to sustain broad access. The transition window forces material regulatory and data‑generation work, risking revenue continuity and label/coverage outcomes.
Nasdaq Listing Deficiency / Liquidity RiskA bid‑price deficiency notice exposes the company to remedial actions, potential transfer or delisting. Deterioration in listing status can reduce liquidity, institutional ownership and access to capital, complicating fundraising while cash burn and development needs remain elevated.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.48 and its highest was $3.07 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $218.01M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Aug 19, 2026 which is in 8 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on May 14, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.073 by -$0.057.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.11.
How many shares outstanding does Invivyd have?
Invivyd has 294,607,450 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.073. Following the earnings report the stock price went down -21.088%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invivyd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (1539.34% Upside)
$10.00 (1539.34% Upside)
Blogger Sentiment
Neutral
IVVD Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
133.02%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
IVVD Company Deck
IVVD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong commercial momentum (PEMGARDA +22% YoY), advancing pivotal trial progress with encouraging safety signals (IDMC reduced monitoring), confirmed neutralization versus a recent Omicron subvariant, an expanding discovery pipeline, and a robust cash position after an April ATM raise. Near-term challenges include elevated clinical spend and burn during the pivotal, continued uncertainty around regulatory outcomes and efficacy readouts driven by event rates, declining COVID vaccine revenue, and imperfect external surveillance and media traction. On balance, concrete operational and scientific progress and expected high efficacy positioning outweigh the near-term financial and market uncertainties.View all IVVD earnings summariesIVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(1539.34% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
9.49% Insiders
7.58% Mutual Funds
0.33% Other Institutional Investors
74.81% Public Companies and Individual Investors